01
Broth microdilution
Accurate and phenotypic, but slow and labor-intensive — results land 24 to 72 hours late.
AI-augmented phenotypic AST
Rapid AI-augmented AST to beat antimicrobial resistance
AgariX BioLab delivers multiparametric, AI-powered antibiotic susceptibility testing in 3–6 hours instead of 24–72 — transforming how healthcare fights resistant infections.
- Time to result
- < 4 h
- Phenotypic
- 100%
- Instrument CapEx
- $0
Time to result
Phenotypic
Instrument CapEx
Live AI resistance-signature analysis
ReadingThe challenge
Antimicrobial resistance is a human and economic crisis
Because susceptibility results arrive days late, clinicians are forced to prescribe broad-spectrum, blind therapy — the very practice that accelerates resistance and drives ICU cost.
- 1.27M
- Annual deaths from drug-resistant infections
- 10M
- Projected annual deaths by 2050 without intervention
- $66B
- Yearly healthcare drain from empirical antibiotic failures
- +7.4%
- Mortality risk per hour of delay in sepsis
$400K vs $10K
Average cost of a resistant infection case versus a drug-susceptible case, plus roughly 7.4 extra inpatient days per patient.
Limitations of current AST approaches
02
Genotypic panels
Detect only known resistance genes; they miss phenotypic resistance and novel mechanisms, and give no MIC.
03
Automated systems
VITEK 2 and BD Phoenix still rely on culture growth, with expensive instruments and consumable lock-in.
04
Emerging microfluidics
Promising imaging and chip platforms remain costly, low-throughput, or not yet clinic-ready.
The solution
The AgariX rapid multiparametric AST platform
AgariX keeps the gold standard — true phenotype — while delivering it at molecular speed, on hardware any lab can already afford.
Proprietary cartridges
Single-use microwell arrays that form reproducible bacterial aggregates for consistent, standardized phenotypes.
Multiparametric readouts
Colorimetric metabolic sensors combined with automated visual phenotyping capture far richer signatures than single-signal tests.
AI analytics
Time-series signals are fused by predictive models to call susceptibility and MIC in 3 to 6 hours.
Low-cost hardware
Simple imaging optics and smartphone-compatible capture — no $100K diagnostic box, no CapEx trap.
Technology platform
Multiparametric sensing, AI-powered analysis
Optical kinetics, metabolic sensing and deep neural nets working on one cartridge — hardware agnostic and compatible with standard commercial optics.
013D microarray innovation
Miniaturized bacterial cultures in precision-engineered arrays enable rapid, parallel testing of multiple antibiotics simultaneously.
02Integrated sensors
Colorimetric detection with automated imaging provides real-time bacterial growth monitoring and precise susceptibility determination.
03AI-powered analytics
Advanced algorithms detect early resistance signatures and heteroresistant subpopulations invisible to traditional methods.
Speed advantage
Time-to-result disruption
Phenotypic accuracy at the speed of molecular testing, with none of the instrument overhead.
Traditional lab culture
48 hrs
Genotypic PCR (no MIC)
8 hrs
AgariX AI-AST
< 4 hrs
| Metric | Standard automated AST | Genotypic PCR panels | AgariX rapid AI-AST |
|---|---|---|---|
| Time-to-result | 24 – 48 hours | 4 – 8 hours | < 4 hours |
| Phenotypic testing | Yes (slow growth) | No (gene marker only) | Yes (real-time kinetic) |
| Consumable expense | $15 – $25 | $120 – $200 | $30 |
| CapEx footprint | $80,000+ | $45,000+ | None (optical software app) |
Product & clinical workflow
From sample to actionable report in one shift
The AgariX workflow mirrors current lab practice, so results land inside the same visit rather than days later.
- 1
Sample processing
Receive a clinical isolate or positive blood culture and load it into a single-use AgariX microwell cartridge with calibrated antibiotic gradients.
- 2
Cartridge insertion
Insert the cartridge into the imaging cradle or smartphone adapter — minimal training, no workflow redesign.
- 3
Real-time detection
Colorimetric sensors and high-resolution automated imaging capture metabolic and morphological time-series data across the run.
- 4
AI analysis
Cloud or local models interpret complex growth patterns and return a susceptibility report with interpretive guidance.
Clinical applications
Built for every point in the chain of care
From bedside decisions to national stewardship programs, rapid phenotypic AST changes what is possible.
Healthcare providers
Seamless integration into existing clinical workflows for immediate impact on patient care.
- Faster targeted therapy decisions
- Reduced hospital stays and costs
- Improved patient outcomes
Hospitals & reference labs
High-throughput, scalable testing that fits the microbiology bench as it exists today.
- Integration with existing microbiology workflows
- Lower reliance on empiric prescribing
- Recurring, low-cost consumables
Global health organizations
Point-of-care testing capability for rapid treatment decisions in any setting.
- Expand access to rapid diagnostics in low-resource regions
- Support antibiotic stewardship programs
- Contribute to global AMR mitigation strategies
About us
A biotechnology company built around one urgent problem
Who we are
AgariX BioLab is a biotechnology company dedicated to tackling the global crisis of antimicrobial resistance. Our mission is to empower healthcare providers with rapid, reliable, and scalable tools for antibiotic susceptibility testing.
Our vision
To accelerate time-to-effective therapy and safeguard antibiotics for future generations by redefining how the world diagnoses and combats bacterial infections.
Our team
We combine expertise in microbiology, bioengineering, AI, and clinical diagnostics to deliver transformative solutions for patients, hospitals, and global health systems.
Our partners
Apricell Biotechnology
Core microwell array patent licensor
Clinical microbiology partners
Multi-site validation pilots